Lysophospholipids and their receptors in the central nervous system
- Authors
- Choi, Ji Woong; Chun, Jerold
- Issue Date
- Jan-2013
- Publisher
- ELSEVIER SCIENCE BV
- Keywords
- Lysophosphatidic acid; Sphingosine 1-phosphate; G protein-coupled receptor; Central nervous system; CNS disease
- Citation
- BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, v.1831, no.1, pp.20 - 32
- Journal Title
- BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Volume
- 1831
- Number
- 1
- Start Page
- 20
- End Page
- 32
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14831
- DOI
- 10.1016/j.bbalip.2012.07.015
- ISSN
- 1388-1981
- Abstract
- Lysophosphatidic acid (LPA) and sphingosine 1-phosphate (S1P), two of the best-studied lysophospholipids, are known to influence diverse biological events, including organismal development as well as function and pathogenesis within multiple organ systems. These functional roles are due to a family of at least 11 G protein-coupled receptors (GPCRs), named LPA(1-6) and SIP1-5, which are widely distributed throughout the body and that activate multiple effector pathways initiated by a range of heterotrimeric G proteins including G(i/o), G(12/13), G(q) and G(s), with actual activation dependent on receptor subtypes. In the central nervous system (CNS), a major locus for these signaling pathways, LPA and SIP have been shown to influence myriad responses in neurons and glial cell types through their cognate receptors. These receptor-mediated activities can contribute to disease pathogenesis and have therapeutic relevance to human CNS disorders as demonstrated for multiple sclerosis (MS) and possibly others that include congenital hydrocephalus, ischemic stroke, neurotrauma, neuropsychiatric disorders, developmental disorders, seizures, hearing loss, and Sandhoff disease, based upon the experimental literature. In particular, FTY720 (fingolimod, Gilenya, Novartis Pharma, AG) that becomes an analog of S1P upon phosphorylation, was approved by the FDA in 2010 as a first oral treatment for MS, validating this class of receptors as medicinal targets. This review will provide an overview and update on the biological functions of LPA and SIP signaling in the CNS, with a focus on results from studies using genetic null mutants for LPA and SIP receptors. This article is part of a Special Issue entitled Advances in Lysophospholipid Research. (C) 2012 Published by Elsevier B.V.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 약학대학 > 약학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14831)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.